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Until recently, intravenous cyclophosphamide pulses with
oral corticosteroids were regarded standard therapy for
proliferative lupus nephritis (LN). Azathioprine, a less toxic
alternative, was never proven to be inferior. In the first Dutch
lupus nephritis study (enrollment between 1995 and 2001),
we randomized 87 proliferative LN patients to either
cyclophosphamide pulses (750 mg/m2, 13 pulses in 2 years)
combined with oral prednisone (CY) or to azathioprine
(2 mg/kg/day in 2 years) combined with intravenous pulses
of methylprednisolone (3 3 pulses of 1000 mg) and oral
prednisone (AZA). After a median follow-up of 5.7 years
(interquartile range 4.1–7.2 years), doubling of serum
creatinine was more frequent in the AZA group, although not
statistically significant (relative risk (RR): 4.1, with 95%
confidence interval (95% CI): 0.8–20.4). Relapses occurred
more often in the AZA group (RR: 8.8, 95% CI: 1.5–31.8).
Creatinine and proteinuria at last visit did not differ between
the two treatment arms. Moreover, 88.4% of the patients in
the AZA arm were still free of cyclophosphamide treatment.
During the first 2 years, the frequency of remission was not
different, but infections, especially herpes zoster virus
infections (HZV) were more frequent in the AZA group.
Parameters for ovarian function did not differ between the
two groups. In conclusion, in this open-label randomized
controlled trial, cyclophosphamide was superior to
azathioprine with regard to renal relapses and HZV. At last
follow-up, there were no differences in serum creatinine or
proteinuria between the two groups. However, since our
study lacked sufficient power, longer follow-up is needed to
reveal putative differences.
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Combined treatment with corticosteroids and a cytotoxic
immunosuppressive drug is considered standard therapy in
proliferative lupus nephritis (LN).1 However, there is no
consensus, whether cyclophosphamide or azathioprine is the
preferable drug.2 In recent years, other options, for example
mycophenolate mofetil, have become available and are
currently evaluated in clinical studies.
Studies conducted by the National Institutes of Health
showed best results for all cyclophosphamide containing
regimens compared to corticosteroids alone.3,4 Intravenous
pulses of cyclophosphamide were as efficacious as oral
cyclophosphamide, but showed less side effects.3 Thus, at
the time we started this study in 1995, the combination of
prednisone and cyclophosphamide intravenously was
accepted as the standard treatment for patients with prolife-
rative LN. However, in the studies published until 1995,
the results of treatment with azathioprine did not differ
significantly from those obtained with cyclophosphamide
containing arms.3–5 Cyclophosphamide has many side
effects, in particular amenorrhea6,7 and malignancies, while
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azathioprine is a drug with less severe long-term side
effects.2,8 Since most patients with systemic lupus erythema-
tosus (SLE) are young females, an effective therapy associated
with a low risk of infertility is warranted.9 We therefore
performed a randomized controlled study to compare the
efficacy of cyclophosphamide pulses with azathioprine and
intravenous methylprednisolone (i.v.MP) as induction the-
rapy for proliferative LN.
The combination treatment of i.v.MP and azathioprine was
preferred to i.v.MP alone, since treatment with six monthly
doses of i.v.MP alone was associated with an increased risk of
doubling of serum creatinine as compared to cyclophos-
phamide containing regimens.10 We argued that azathioprine
would halt the progression of chronic lesions,11 while i.v.MP
would more rapidly affect acute inflammation.12,13 In an
uncontrolled study, this regimen of azathioprine with i.v.MP
and low doses of oral prednisone was found to be effective and
associated with minimal toxicity.14
With our study we intended to shed more light on
azathioprine as a valuable alternative for cyclophosphamide,
thereby anticipating that this could result in an increased but
acceptable number of patients reaching the study end point
(doubling of serum creatinine). This paper describes the
results in 87 patients with biopsy-proven proliferative LN
with a minimum follow-up of 3 years, and a median follow-
up of 5.7 years.
RESULTS
Baseline characteristics and treatment
The baseline characteristics of the 87 patients are shown in
Table 1. The stratification per center in combination with a
small contribution of some centers unintendedly resulted in a
skewed distribution: 50 patients were included in the
cyclophosphamide (CY) group and 37 in the azathioprine/
methylprednisolone (AZA) group. Of the 87 patients, 49
(56%) presented with renal impairment (estimated creatinine
clearance according to Cockcroft and Gault o70 ml/min15),
46 (53%) were nephrotic (proteinuria 43.5 g/24 h), and in
36 patients (41%) nephritis was the presenting symptom of
SLE. Previous treatment with cytotoxic agents for prolife-
rative LN had been given to 13 patients (15%). The baseline
parameters between the two treatment arms did not differ.
In nine patients, the treatment according to the study
protocol was prematurely discontinued (details are given in
the trial profile in the Appendix B): in the CY group because
of toxicity (n¼ 3), life-threatening infection (n¼ 1), and non-
compliance (n¼ 2); in the AZA group because of malignancy
(n¼ 1), noncompliance (n¼ 1), and withdrawal by the
physician (n¼ 1). Three patients (3.4%) were lost to follow-up.
The median number of cyclophosphamide pulses was 13
(interquartile range (IQR) 11.8–13), with a median cumula-
tive dose of 15.6 g (IQR 12.3–16.9).
Renal biopsies
There were no differences in WHO-classification (III versus
IV) or in the activity and chronicity indices between the two
treatment arms. In 62% of all patients, the randomization
was performed within 2 weeks after the biopsy was obtained
(median 7 days, IQR 5–21). In 12 patients (14%) this period
was longer than 1 month. The distribution of the biopsies
attained within or longer than a month before randomiza-
tion was equal in both treatment arms. Also, there were
no differences in the chronicity and activity indices in the
biopsies attained within or longer than a month before
randomization.
Reviewing all biopsies according to the new ISN/RPS 2003
classification for LN16 showed an equal distribution of the
new classification subtypes, segmental and global, in both
treatment arms.
Outcome
In the autumn of 2004, the median follow-up was 5.7 years
(IQR 4.1–7.2): for the CY group 5.5 years (IQR 3.9–6.6) and
for the AZA group 6.3 years (IQR 4.2–8.2), respectively. Both
the CY and AZA group performed better than we had
Table 1 | Baseline characteristics of 87 patients with
proliferative lupus nephritis
Characteristic CY AZA
n=50 n=37
Female gender (%) 88 84
Caucasian (%) 80 70
Age (years) 30 (24–47) 33 (26–39)
Age at diagnosis of lupus (years) 26 (20–41) 26 (22–35)
LN presenting symptom (%) 40 43
LN in past (%) 18 16
Cytotoxic agents for LN in past (%) 14 16
Hypertension present (%) 62 51
Systolic blood pressure (mm Hg) 140 (120–150) 140 (120–150)
Diastolic blood pressure (mm Hg) 80 (80–90) 80 (70–90)
Use of antihypertensive drugs (%) 66 51
SLEDAI 19 (14–24) 20 (16–22)
Randomization after biopsy (days) 7 (5–20) 13 (5–24)
Biopsy parameters
WHO-class III or Vc (%) 10 8
WHO-class IV or Vd (%) 90 92
Activity index 9.5 (7.3–11.3) 9.3 (5.8–11.7)
Chronicity index 2.7 (2.0–3.7) 2.3 (1.7–3.3)
Laboratory parameters
Serum creatinine (mmol/l)a 112 (86–153) 109 (83–161)
Creatinine clearance (ml/min)b 65 (45–83) 66 (42–96)
Serum C3 (g/l) 0.50 (0.35–0.64) 0.50 (0.39–0.65)
Serum C4 (g/l) 0.10 (0.08–0.15) 0.11 (0.07–0.17)
Anti-dsDNA (IU/ml) 172 (31–632) 142 (25–517)
Hematuria (45 RBC/hpf) (%) 78 78
Leukocyturia (45 WBC/hpf) (%) 72 76
Casts present (%) 42 43
Proteinuria (g/24 h) 4.3 (2.2–6.5) 3.2 (2.0–5.9)
anti-dsDNA, anti-double-stranded DNA antibodies; AZA, azathioprine/methylpred-
nisolone/prednisone; C3, complement C3; C4, complement C4; CY, cyclo-
phosphamide/prednisone; LN, proliferative lupus nephritis; RBC, red blood cells;
hpf, high-power field; SLEDAI, SLE disease activity index; WBC, white blood cells;
WHO, World Health Organization.
Data are given as medians and interquartile ranges, or as percentages.
aTo convert values of creatinine to milligrams per deciliter, divide by 88.4.
bEstimated creatinine clearance according to Cockcroft and Gault.
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anticipated in the power calculation. The proportion of
patients that reached the primary end point (nonsustained
doubling of initial serum creatinine) did not differ sig-
nificantly between the two arms (Figure 1a; relative risk (RR)
4.1, 95% confidence interval (95% CI): 0.8–20.4), but the
95% CI suggests a higher future chance of doubling of serum
creatinine in the AZA group.
Nevertheless, the estimated absolute difference in reaching
the primary end point between the two treatment arms
is 12.5% (95% CI: 1.0 to 26.0%), which falls within the
limits used for the power calculation (i.e. a 20% difference
between CY and AZA group). The final outcome for the
various treatment related events is summarized in Table 2.
Relapses occurred significantly more often in the AZA
group (RR: 8.8, 95% CI: 1.5–31.8) (Figure 1b). There were no
differences in the activity or chronicity indices in renal
biopsies between patients who experienced a relapse
compared to those who did not.
During follow-up five patients died: two in the CY arm
(weeks 4 and 16) and three in the AZA arm (weeks 44, 188,
and 362) (Figure 1c).
The course of serum creatinine and proteinuria in those
patients who experienced a relapse is given in Figure 2. Both
serum creatinine and proteinuria decreased in most patients,
indicating that the relapses could be treated effectively so far.
This is in line with the observation that at last visit the
median serum creatinine and proteinuria were 80 mmol/l
(IQR 70–104) and 0.2 g/24 h (IQR 0.1–0.8) in the cyclo-
phosphamide group, and 86 mmol/l (IQR 76–114) and 0.4 g/
24 h (IQR 0.1–1.15) in the azathioprine group, respectively
(differences between groups not significant).
More women in the CY group became pregnant (see
Table 2), but the difference between both treatment arms was
not statistically significant. In both groups two patients were
diagnosed with premature ovarian failure (POF). Both
patients in the AZA arm with POF were treated with
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Figure 1 | Kaplan–Meier estimates. Kaplan–Meier curves showing (a) proportion of patients reaching the end point of the study, nonsustained
doubling of serum creatinine, (b) proportion of patients free of relapse, and (c) proportion of patients free of treatment failure, relapse, or
death. RR and 95% CI are given. CY¼group treated with intravenous cyclophosphamide and oral prednisone, AZA¼group treated with i.v.MP,
azathioprine, and oral prednisone.
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cyclophosphamide (one because of a secondary relapse and
one because she developed a non–Hodgkin’s lymphoma).
Three patients in the CY group were unwillingly childless
versus one in the AZA group. The number of women who
became postmenopausal during the study did not differ
between the two treatment arms.
From all patients in the AZA group, 88.4% (95% CI:
77.5–99.3) were still free of cyclophosphamide after a median
follow-up of 6.3 years.
Remissions and disease parameters during the
first 2 years of treatment
The treatment regimen differed between both study arms
only during the first 2 years. To evaluate a difference in
efficacy of the initial treatment, remissions, and disease
parameters were therefore analyzed for this period separately.
The cumulative incidence of the first partial and complete
remission is shown in Figure 3. There were no differences
between the CY and AZA group.
The changes in laboratory values during these first 2 years
in both arms are shown in Figure 4. Serum creatinine
significantly decreased in both treatment arms compared to
pretreatment values (Po0.001).
Also, proteinuria dropped significantly in both groups,
although the initial decrease in proteinuria was faster in the
AZA group. The level of anti-double-stranded DNA anti-
bodies (anti-dsDNA) decreased rapidly without differences
between the two arms (Figure 4c). The serum levels of
complement C3 (Figure 4d) and complement C4 returned to
(sub)normal levels, although from week 12 onwards they
remained lower in the AZA group (for C3 P¼ 0.03 and for
C4 P¼ 0.09). Both the SLE Disease Activity Index17 and
the physician’s visual analog scale (VAS) did not differ
between the treatment groups. These parameters decreased
Table 2 | Outcome at last follow-up
Cyclophosphamide Azathioprine
n=50 n=37
Follow-up (years)
Median 5.5 6.3
Interquartile range 4.1–7.2 3.9–6.6
Primary treatment failure (n) 0 1a
Renal relapse (n) 2 10
Renal relapse rate
(relapse/100 patient years)
1.1 7.1
Reaching study end point (=doubling
of serum creatinine) (n)
2 6
Therapy switch (n) 1 3
ESRDb (n) 0 1a
Death (n) 2c 3c
Became pregnant during
follow-up (n)
9 5
Pregnancies during follow-up (n) 10 10
Unwillingly childless (n) 3 1
Became postmenopausal
during follow-up (n)
6 3
POFd (n) 2 2e
aOccurring in the same patient.
bESRD, end-stage renal disease.
cCause of death in CY arm: sepsis and heart failure (week 4), and ischemic stroke
(week 16). Three patients in the azathioprine arm died: one due to pseudomem-
branous colitis, sepsis, and pneumonia (week 44, after relapsing in week 32) and two
due to stroke (week 188 and week 362).
dPOF=premature ovarian failure: postmenopausal before 40 years of age, proven
with high LH and FSH levels.
eBoth patients were treated with cyclophosphamide, one because of a secondary
relapse (week 104) and one because she developed a non-Hodgkin’s lymphoma
(cumulative cyclophosphamide dose: 14.3 g).
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Figure 2 | Time course of serum creatinine and proteinuria in
patients who had a relapse. (a) Serum creatinine and (b) proteinuria
at (first) relapse and at last follow-up in 12 patients who experienced
a relapse. Serum creatinine is expressed as percentage compared to
the lowest serum creatinine (Screat) before relapse. For two patients
no last follow-up data are given: one patient died 12 weeks after
relapsing, and the other patient is currently treated for a relapse.
Relapses were due to doubling of serum creatinine in six
patients, due to nephrotic syndrome in five patients, and due
to both doubling of serum creatinine and nephrotic syndrome
in one patient.
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significantly and paralleled each other (r¼ 0.673, Po0.01).
After an initial increase, the patient’s VAS did not rise further
after 20 weeks. Notably, the CY and AZA arm did not differ
for this assessment of patient’s well being.
In the first 2 years, a higher infection rate occurred in the
AZA arm: 37 versus 18 events per 100 patient years, RR: 1.4
(95% CI: 1.1–1.8). This higher infection rate was mainly due
to herpes zoster virus (HZV): 12 events per 100 patient years
in the AZA group versus 3 events per 100 patient years in the
CY group, RR: 1.7 (95% CI: 1.2–2.5). Almost all HZV events
in the AZA group occurred in the first 6 months. Hospital
admission for infections was not different between the two
treatment arms (RR 1.1, 95% CI: 0.6–2.0).
One patient in the AZA group suffered from non-
Hodgkin’s lymphoma. No avascular osteonecrosis or hemor-
rhagic cystitis was seen. In each group one patient developed
diabetes.
DISCUSSION
This is the first randomized controlled trial comparing
azathioprine and methylprednisolone with cyclophospha-
mide pulse therapy for the treatment of proliferative LN.
Prior studies involved smaller groups and were most often
(retrospective or prospective) cohort studies,14,18–20 or the
azathioprine-based regimen was compared with oral cyclo-
phosphamide21 or steroids alone.9
After a median follow-up of 5.7 years, there was no
significant difference (RR: 4.1, 95% CI: 0.8–20.4) between the
two groups in the proportion of patients who developed a
doubling of their serum creatinine (primary end point).
However, it has to be acknowledged that since the inclusion
of patients lagged behind, our study was underpowered to
detect a significant difference in the incidence of the primary
end point.
Remarkably, the overall treatment result was better than
we had presumed at the start of the study. As outlined in the
power calculation, we expected that at least 30% would have
doubled their serum creatinine after 5 years of follow-up. In
our cyclophosphamide group, the observed incidence of
doubling of serum creatinine was less than 5%, after a
minimum follow-up of 3 years. However, the unexpectedly
low primary end point rate has no detrimental effect on the
power of the study in terms of risk differences (data not
shown).
The better than expected overall treatment results might
be due to the fact that our patients were mainly Caucasian,
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Figure 4 | Kinetics of laboratory values. Laboratory values (medians) during the first 2 years of therapy: (a) serum creatinine, (b) proteinuria,
(c) anti-double-stranded DNA antibodies (anti-dsDNA), (d) complement 3 (C3). CY, group treated with intravenous cyclophosphamide and oral
prednisone; AZA, group treated with i.v.MP, azathioprine, and oral prednisone.
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and that most of them were treated with long-term
maintenance therapy (advised for at least 7 years). Cessation
of maintenance immunosuppressive therapy in patients with
LN after successful initial treatment was associated with renal
flares in 45%, 18–36 months after cessation, with 27%
progressing to end-stage renal disease.22
Another explanation for the favorable outcome could be
that, in the last decades, patients known to have lupus are
referred earlier for renal biopsy, and as a consequence start
earlier with immunosuppressive treatment.23,24
One could also argue that our patients had a mild degree
of renal impairment at the start of treatment. However, in
our study, the median serum creatinine was either lower10,25
or higher3,26,27 than that reported in other studies. Therefore,
our population falls within the spectrum observed by others.
During the first 2 years of therapy, the cumulative
incidence of partial or complete renal remission was not
different between the two arms, suggesting that the efficacy of
induction therapy with azathioprine and methylprednisolone
is comparable with that of cyclophosphamide. However, after
a median follow-up of 5.7 years, we observed more relapses
in the azathioprine group. Concurrently, there was a trend
towards a higher incidence of doubling of initial serum
creatinine. Taken together, this indicates that CY is superior
in terms of efficacy. The lower complement measurements
from week 12 onwards in the azathioprine group underscore
this possibility, since low complement is a predictor of worse
renal outcome.28,29
Since renal flares are known to be a risk factor for
deterioration of renal function,28,30 extended follow-up is
necessary to disclose whether renal function remains
preserved in those who experienced a relapse. Fortunately,
in many of these cases, renal function could be restored and
proteinuria reduced by reinduction treatment (in case of a
relapse) or switch to the alternative treatment (in case of
treatment failure). This is reflected by the observation that at
the end of follow-up, serum creatinine and proteinuria were
similar in both groups. However, these are not the most
sensitive markers of kidney damage.
During the first 2 years, infectious events were seen more
often in the azathioprine arm. HZV is most often described
in patients treated with cyclophosphamide,31 but also
associated with azathioprine treatment.32 Since HZV mainly
occurred in the first 6 months, we assume that the larger dose
of corticosteroids in the AZA group has a more important
role than azathioprine.
One of the main reasons to consider an alternative
treatment for cyclophosphamide in the mostly young female
lupus patients is the risk of infertility. Young women who
eventually want to become pregnant will often choose a
treatment option that is associated with better preservation
of ovarian function even if the risk for renal relapse is
larger.33 We found no differences in the number of
pregnancies or unwilling childlessness in the treatment arms.
However, all four patients who developed POF received
cyclophosphamide. The small groups, the short duration of
follow-up, and the large number of patients who are
currently using hormonal contraceptives make it difficult to
draw definitive conclusions, but the effect of cyclopho-
sphamide regarding gonadal toxicity was clearly shown in the
past.6,7,34,35
In this regard, it should be noted that after a median
follow-up of 6.3 years, more than 80% of the patients in the
azathioprine group were free of cyclophosphamide and
therefore have a better prognosis regarding fertility. However,
a recent study by Somers et al.36 showed that monthly
injections with a gonadotropin-releasing hormone analog
was associated with a significant reduction of POF in 40
women with severe SLE, treated with monthly intravenous
cyclophosphamide, as compared to matched controls, treated
with intravenous cyclophosphamide but not with gonado-
tropin-releasing hormone analog. With this promising
method for ovarian protection, the frequency of the most
important side effect of cyclophosphamide treatment can be
reduced.
Until now we did not find differences in steroid-related
complications. However, due to the higher cumulative dose
of corticosteroids in the azathioprine/methylprednisolone
group differences might become manifest after a longer
follow-up.
Although we studied a relatively large number of patients
with proliferative LN in a controlled randomized trial, our
study has several limitations. First, patients were stratified per
center, which inadvertently resulted in a skewed distribution
over the two treatment arms. This unbalance has hardly any
effect on the power of the study, since analysis of 50 versus 37
patients has the same power as 42 versus 43 patients.37 So, the
loss of efficiency is only 2% (2/87). Second, we did not
manage to include as many patients as we aimed for based on
the power calculation. Nevertheless, the number of patients
included is equal to that in the largest randomized controlled
trials with a long-term follow-up reported so far.26,38 Third,
this paper describes the results after a minimum follow-up of
3 years, while it is known that a follow-up of at least 5 years is
necessary to evaluate the long-term effects on renal function.4
However, other long-term studies had comparable periods
of follow-up and, in their experimental treatment arm, found
comparable cumulative percentages of doubling of serum
creatinine (up to 20%) as we did.39,40 Fourth, although often
used, the end point of doubling of serum creatinine remains
a surrogate end point for future development of end-stage
renal disease. In the majority of our patients, doubling of
serum creatinine disappeared after intensification of im-
munosuppressive treatment (see Figure 2a).
Recently, other alternatives for the standard treatment
with cyclophosphamide pulses were published. In a Chinese
population, it was demonstrated that after 12 months
induction therapy with mycophenolate mofetil (MMF),
81% reached complete remission as compared to 76% in
the control group treated with 6 months oral cyclopho-
sphamide followed by azathioprine.41 After 63 months
follow-up in an extended population of 62 patients, an
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incidence of doubling of serum creatinine was observed in 6
versus 10%, with a reduced frequency of gonadal toxicity and
other side effects.39 With very stringent remission criteria,
Ginzler et al.27 recently showed a superior effect of MMF in
inducing remission in 140, mainly black, patients during 24
weeks of treatment with either MMF or intravenous
cyclophosphamide (complete remission 23 versus 6%, and
partial remission 30 versus 25%). These promising results
have raised the possibility that MMF could become the
treatment of choice for proliferative LN. Nevertheless, longer
follow-up is needed to study its long-term efficacy and safety.
At this moment, pregnancy during MMF treatment is
contraindicated.
Since gonadal toxicity of cyclophosphamide is related to
age and cumulative dose,7,42,43 reduction of the dose may
sufficiently decrease the risk of POF. In the Euro-lupus trial,
short-term cyclophosphamide pulses (six low dose pulses
every fortnight for 3 months; cumulative dose 3 g) and
azathioprine from 3 months onwards were compared to six
monthly pulses of cyclophosphamide and two quarterly
pulses thereafter (cumulative dose 9 g). At 73 months no
differences were found between the two treatment arms:
cumulative percentage of doubling of serum creatinine: 20%
in low-dose group versus 10% in high-dose group.40
Contreras et al.25 reported that after six monthly pulses of
cyclophosphamide, maintenance therapy with azathioprine
or MMF was associated with better patient survival and renal
outcome than maintenance therapy with quarterly pulses of
cyclophosphamide. However, in that study the mortality in
the cyclophosphamide group was higher than generally
observed.
In conclusion, in our patient cohort, cyclophosphamide
pulse therapy was superior to azathioprine/methylpredniso-
lone with regard to relapses and short-term infections.
However, so far renal function at last visit did not differ
between the groups. Owing to the limited power of our study,
long-term follow-up is needed to draw final conclusions for
the preservation of renal function, especially in those patients
who experienced a relapse. Currently, azathioprine/methyl-
prednisolone induction treatment for LN should therefore be
reserved only for those patients with a strong wish to con-
ceive and with a high risk of POF, who are willing to accept
the higher risk of exacerbations and infections. They should
also be informed about current possibilities for gonadal
protection with gonadotropin-releasing hormone analog
during cyclophosphamide treatment. In addition, MMF
appears to be a promising alternative for cyclophosphamide.
MATERIALS AND METHODS
Patient selection
Between September 1995 and September 2001, 87 patients were
enrolled in the first Dutch Lupus Nephritis Study.44 From all
patients with proliferative LN, diagnosed by biopsy, as revealed by
the national pathology registry (PALGA), more than 60% fulfilled
the inclusion criteria. From these, 60% were willing to participate.
The main reason not to participate was a strong wish to conceive.
All study patients met the following criteria: the presence of Z4
American College of Rheumatology criteria for SLE,45 age 18 to 60
years, creatinine clearance (Cockcroft–Gault) 425 ml/min, and
biopsy-proven proliferative LN.46 For patients already known to
have proliferative LN, the last renal biopsy had to be performed less
than one year before. Patients with WHO-class IV or Vd LN were
eligible when they had signs of active nephritis or a deterioration of
renal function. Patients with WHO-class III or Vc LN had to meet
both criteria. Patients with membranous LN WHO-class Va or Vb
were excluded. Details on definitions and exclusion criteria are given
in Appendix B.
The ethics committees of all participating hospitals approved the
study. Written informed consent was obtained from all subjects. The
study was conducted according to the Declaration of Helsinki
Principles.
Renal biopsies
Before randomization all biopsies were reviewed and classified by at
least one of three experienced nephropathologists (KA, JAB, and
JW), according to the 1995 WHO criteria.46 Activity and chronicity
indices were scored as described.47
Randomization
Randomization was performed at a central office with a computer
program, using the following minimization determinants:
center, serum creatinine (o150 or 4150 mmol/l), WHO-class III
or IV, and previous treatment with immunosuppressive medication
for LN.
Treatment
Details of the study protocol are given in Appendix B. Patients in the
CY group received pulse cyclophosphamide (750 mg/m2) every 4
weeks for a total of six pulses, followed by seven pulses every 12
weeks. Cyclophosphamide was combined with oral prednisone:
initially 1 mg/kg/day, tapered to a final dose of 10 mg daily after 6
months. Patients in the AZA group started with azathioprine (2 mg/
kg/day) at day one, combined with methylprednisolone intrave-
nously (1000 mg) on three consecutive days. This cycle of three
pulses was repeated after 2 and 6 weeks. In addition, oral prednisone
(20 mg/day) was given for 5 months and then tapered to 10 mg/day.
The study had an open-label design. During the first 2 years, the
cumulative corticosteroid dose administered to a patient in the AZA
group was 20 g (11 g for i.v.MP and 9 g for oral prednisone), while in
the CY group this was 11 g for a person weighing 70 kg. After 2 years
the therapy was identical in both groups, that is, azathioprine 2 mg/
kg/day combined with prednisone 10 mg/day (cumulative corticos-
teroid dose from year 2 to 4: 7 g). Four years after inclusion, it was
advised to taper the dosage of both drugs over a year; first
prednisone to 10 mg every other day and thereafter azathioprine to
1 mg/kg/day. This regimen was advised to continue for at least 2
more years.
All patients were followed for the intention-to-treat analysis.
Assessments
Clinical and laboratory parameters, adverse events, pregnancies, and
infections were recorded. Patients were asked to score their general
well being on a VAS, from 0 to 10. Patients were asked ‘How did you
feel during the past month?’, a higher number representing a higher
degree of general well being (patient’s VAS). Disease activity was
measured by physicians on a VAS, ranging from ‘not active at all’ (0)
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to ‘very active’ (10) (physician’s VAS), and by calculating the SLE
Disease Activity Index.17
At last visit fertility was analyzed using a questionnaire
evaluating pregnancies during follow-up, unwilling childlessness
and development of menopause. Also, luteinizing hormone and
follicle stimulating hormone levels were measured. Postmenopause
was defined as sustained amenorrhea proven with high luteinizing
hormone and follicle stimulating hormone levels, and POF as
becoming postmenopausal before 40 years of age.
Outcome
The primary study end point was (nonsustained) doubling of
baseline serum creatinine. Secondary end points were treatment
failure and relapse, end-stage renal disease, mortality, adverse events
(especially infections and infertility), and quality of life. Renal
parameters at last visit consisted of both serum creatinine and
proteinuria.
Definitions
Primary treatment failure was evaluated at week 12, and was defined
as doubling of baseline serum creatinine. In case of failure patients
were switched to the other treatment arm.
A relapse could occur after week 12, and was defined as doubling
of the lowest obtained serum creatinine so far and/or development
of either a nephrotic syndrome (proteinuria 43.5 g/day and serum
albumino30 g/l), while the lowest protein excretion so far had been
p2.0 g/day repeatedly, or proteinuria 41.5 g/day without other
causes, in a previously nonproteinuric patient. In case of a relapse,
the induction therapy was repeated. If that course failed (secondary
treatment failure), or in case of a second relapse, the patient switched
to the other treatment arm.
Complete remission was defined as a serum creatinine o130% of
the lowest serum creatinine since start of treatment, proteinuria
o0.5 g/day, ando10 erythrocytes/hpf. Partial remission was defined
as stable or improved serum creatinine and at least 50% decrease of
proteinuria, to less than 3 g/24 h (remission criteria adapted from
Illei et al.22).
Statistical analysis
Power calculation. According to the literature, we expected
that, after a follow-up of 5 years, 30% of the patients would have
developed a doubling of their serum creatinine.3,10 In order to allow
detection of a 20% difference between the two patient groups
(i.e. 50% doubling of serum creatinine in the azathioprine group,
after 5 years of therapy), 100 patients were required with one-tailed
testing (with a¼ 0.05 and b¼ 0.80). Unfortunately, even after
extension of the inclusion period to 6 years, 87 patients were
included.
Data analysis. All data were analyzed on an intention-to-treat
basis using SPSS 12.0.1. Descriptive statistics included frequency
tables of patient characteristics, baseline variables, and fertility
parameters. Comparisons were made with Mann–Whitney U tests.
Kaplan–Meier curves and log-rank statistics were used for
comparisons between the two treatment arms for events and
achievement of remission. RR ratios and 95% CI were calculated for
the events treatment failure or relapse using Cox regression analysis.
Differences between the two groups with regard to laboratory values
and activity measurements were studied with repeated measure-
ments mixed model tests. Infections and hospitalization for
infections were expressed as number of episodes per 100 patient
years, and for risk and 95% CI calculations Cox regression analysis
was used. A P-value o0.05 was regarded statistically significant.
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Appendix B
SUMMARY OF STUDY PROTOCOL: DUTCH LUPUS
NEPHRITIS STUDY I
Inclusion criteria.
1. Z4 ACR criteria for SLE
2. age 18–60 years
3. creatinine clearance 425 ml/min (Cockcroft-Gault
formula)
4. biopsy-proven proliferative lupus nephritis
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For patients already known to have LN, the last renal
biopsy had to be performed less than one year before.
Patients with WHO-class IV or Vd LN had to have either
signs of active nephritis (defined as repeated erythrocyturia
(45 dysmorphic erythrocytes per high-power field) and
occurrence or recurrence of proteinuria 41.5 g/day or
doubling of proteinuria, to at least 3.5 g/day), or a
deterioration of renal function (defined as 30% increase of
serum creatinine within 3 months or an impaired renal
function with a creatinine clearance of 25–70 ml/min,
according to Cockcroft and Gault, in case previous renal
function was unknown). All patients with class III or Vc LN
had to meet both criteria.
Exclusion criteria.
1. decline in renal function (more than 30% increase in
serum creatinine) during treatment with cytotoxic
immunosuppressive agents in the month before inclusion.
2. active infection.
3. malignancy o5 years before randomization.
4. pregnancy or refusal to use reliable contraceptives during
the first 2.5 years of treatment.
5. chronic active or persisting hepatitis or cirrhosis of the
liver.
6. active peptic ulcer.
7. leukocytopenia (o3.0 109/l) or thrombocytopenia
(o100 109/l), with suppressed bone marrow (as shown
in a bone marrow aspirate).
8. known allergy for azathioprine or cyclophosphamide.
Treatment. After establishment of study eligibility and
after obtaining written informed consent, patients were
randomized to one of two open-label treatment groups. The
following minimization determinants were used: center,
serum creatinine (o150 or 4150 mmol/l), classification of
renal biopsy findings (WHO-class III or IV), and previous
treatment with immunosuppressive medication for lupus
nephritis.
Patients in the cyclophosphamide group (CY) received
pulse cyclophosphamide (750 mg/m2) every 4 weeks for a
total of six pulses, followed by seven pulses every 12 weeks.
Protection of the bladder was accomplished by administration
of mesna (natrium-2-mercapto-ethane sulfonate), three times
20% of cyclophosphamide dose, and by hyperhydration (at
least 1000 ml saline/glucose in 8 h). The cyclophosphamide
was combined with oral prednisone: initially 1 mg/kg/day
for 4 weeks, 0.75 mg/kg/day for 4 weeks, 0.50 mg/kg/day for
4 weeks and thereafter tapered by 5 mg every 4 weeks to a
final dose of 10 mg daily after 6 months. Patients in
the azathioprine group (AZA) started with azathioprine
(2 mg/kg/day) at day one. The azathioprine was combined
with i.v. MP (1000 mg) on three consecutive days. This cycle
of three pulses was repeated after 2 weeks and after 6 weeks
resulting in a total of nine pulses. Oral prednisone (20 mg/
day) was added and tapered to 10 mg after 5 months.
From 2 years after randomization the therapy was
identical in both groups, that is, azathioprine 2 mg/kg
combined with prednisone 10 mg/day. Four years after start
of study medication, it was advised to sequentially taper the
dosage of both drugs over a year; first prednisone to 10 mg
every other day and thereafter azathioprine to 1 mg/kg/day.
This regimen was continued for at least 2 more years.
During the study period, participants were followed at
least every 4 weeks during the first 6 months and three-
monthly from 6 months onwards. After 4 years physicians
were asked to follow patients on a regular basis. Each visit
weight, blood pressure and current medication were
recorded, and adverse events were evaluated. Infections were
recorded; in case of hospitalization the causing microorgan-
ism and treatment were logged too. HZV infections were
documented separately.
Failure or relapse. Primary treatment failure was evaluated
at week 12, and was defined as doubling of baseline serum
creatinine. In case of failure patients were switched to the
other treatment arm.
A relapse could occur after week 12, and was defined as
doubling of the lowest obtained serum creatinine so far and/
or development of either a nephrotic syndrome (proteinuria
43.5 g/day and serum albumin o30 g/l), while the lowest
protein excretion so far had been p2.0 g/day repeatedly, or
proteinuria 41.5 g/day without other causes, in a previously
nonproteinuric patient. In case of a relapse, the induction
therapy was repeated. If that course failed (secondary
treatment failure), or in case of a second relapse, the patient
also switched to the other treatment arm.
Treatment adjustments. In case of an impaired renal
function (o40 ml/min), the cyclophosphamide dose was
adjusted to 500 mg/m2. If 2 weeks after the administration of
cyclophosphamide, the nadir of white blood cells was
o2.0 109/l and/or platelet count was o100 109/l, 75%
of the initial cyclophosphamide dose was given the following
time. If cytopenia ensued again, the patient continued to
receive 75% of the original cyclophosphamide dose through-
out the study.
When during azathioprine treatment white blood cell
count was between 3.0 and 3.5 109/l, the dosage was halved.
It was temporarily discontinued if white blood cell count
dropped below 3.0 109/l and/or platelets count was
o100 109/l. After recovery of hematological parameters
azathioprine was prescribed again, and the dose was
gradually increased until the maximally tolerated dose. When
during treatment with azathioprine the transaminases were
elevated above three times the upper limit of normal values
during at least 3 months, the dosage was reduced to 50%.
After normalization of liver function tests, the effect of the
full dose was reevaluated. In case of elevation of transami-
nases above five times the upper limit of normal values,
azathioprine was withdrawn until normalization and then
introduced again (starting with 50% of original dose, and
after 3 months the original dose was given unless transami-
nases had risen again). Recommendations for the treatment
of hypertension and hyperlipidemia were given, but the
choice of drugs was left to the physician. At start of the study,
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in 1995, the blood pressure needed to be r140/90 mm Hg.
From March 1998 the prescription of ACE-inhibitors in case
of proteinuria above 0.5 g/24 h was compulsory. Osteoporosis
prophylaxis (calcium, and in some cases also vitamin D) was
given to all patients. The choice of contraceptives was free.
Cimetidine use was prohibited because of its inhibitory effect
on the tubular secretion of creatinine.
In case of extra-renal exacerbations it was allowed to
increase prednisone up to 1 mg/kg/day, to be tapered in a
short period of time. If cytotoxic immunosuppressive therapy
needed to be changed, the patient was withdrawn from the
study protocol and treated according to the decisions of the
physician. Nevertheless, all patients were followed for the
intention-to-treat analysis.
87 patients enrolled in the study
50 patients randomized to cyclophosphamide 37 patients randomized to azathioprine
1 non-compliance (from week 32) 
6 complications: 
3 cyclophosphamide toxicities (week 20 (2×) and 
week 80)
1 life threatening infection (week 4) 
2 deaths (week 4 and week 16)
1 lost to follow-up (week 16)1 lost to follow-up (week 50)
1 non-compliance (=both azathioprine and prednisone
were tapered from week 32) 
1 withdrawn (physician's decision) (week 40) 
2 complications: 
1 malignancy (week 44) 
1 death (week 44)
42 patients treated according to the study protocol
during 104 weeks
32 patients treated according to the study protocol 
during 104 weeks
After week 104: After week 104: 
2 deaths (week 188 and week 362) 1 non-compliance (refused aza from week 104) 
1 lost to follow-up (from week 195)
In 2004:
Follow-up data available from 46/50 patients
In 2004:
Follow-up data available from 33/37 patients
Trial profile
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